Loading…
Anuh Pharma (ANUHPHR)₹82.78−0.01%Pharmaceuticals
In the Jun 2026 quarter (standalone), Anuh Pharma reported sales of ₹195 Cr, up 4.3% from Jun 2025, and net profit of ₹10.98 Cr, up 37.6% year on year. For the year to Mar 2026, sales were ₹776 Cr and net profit ₹40.96 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 151 | 173 | 165 | 139 | 167 | 161 | 199 | 187 | 187 | 198 | 203 | 195 |
| Expenses | 131 | 147 | 144 | 126 | 148 | 144 | 178 | 175 | 173 | 177 | 181 | 177 |
| Operating Profit | 17.99 | 24.01 | 18.99 | 10.99 | 16.99 | 15.01 | 18.98 | 9.99 | 11.99 | 18.99 | 19.99 | 15.98 |
| OPM % | 12.1% | 14.1% | 12.0% | 8.0% | 10.0% | 9.0% | 9.1% | 6.0% | 6.0% | 10.0% | 10.0% | 8.0% |
| Other Income | 1.99 | 3.99 | 2.99 | 3.99 | 2.99 | 0.99 | 0.99 | 2.99 | 0.99 | 1.99 | −0.99 | 2.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 1.99 |
| Profit before tax | 18.06 | 25.08 | 20.08 | 12.05 | 18.05 | 13.06 | 17.06 | 11.04 | 10.04 | 18.07 | 16.05 | 17.06 |
| Tax % | 23.0% | 24.0% | 22.0% | 22.0% | 17.0% | 22.0% | 28.0% | 24.0% | 23.0% | 25.0% | 25.0% | 32.0% |
| Net Profit | 13.97 | 18.95 | 14.96 | 9.98 | 14.98 | 9.99 | 11.99 | 7.98 | 7.99 | 12.98 | 11.99 | 10.98 |
| EPS (Rs) | 1.39 | 1.92 | 1.54 | 0.96 | 1.51 | 1.04 | 1.25 | 0.84 | 0.77 | 1.35 | 1.18 | 1.15 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 327 | 207 | 239 | 322 | 308 | 433 | 489 | 529 | 649 | 665 | 776 | 782 |
| Expenses | 288 | 182 | 219 | 290 | 283 | 386 | 438 | 474 | 569 | 598 | 706 | 709 |
| Operating Profit | 37.99 | 23.01 | 17.99 | 30.01 | 22.99 | 44.98 | 47.03 | 51.97 | 75.95 | 61.94 | 61.98 | 66.95 |
| OPM % | 12.1% | 11.0% | 8.1% | 9.0% | 8.0% | 10.1% | 10.1% | 10.0% | 12.0% | 9.1% | 8.0% | 8.6% |
| Other Income | 3.99 | 7.99 | 6.99 | 4.99 | 3.99 | 10.98 | 4.99 | 5.99 | 11.99 | 8.99 | 3.99 | 4.98 |
| Interest | 1.01 | 1.01 | 0.00 | 1.01 | 1.01 | 2.01 | 2.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 |
| Depreciation | 1.99 | 1.99 | 1.99 | 1.99 | 6.98 | 14.95 | 11.95 | 9.97 | 8.97 | 8.97 | 10.95 | 10.96 |
| Profit before tax | 38.11 | 28.11 | 23.07 | 32.12 | 19.08 | 39.12 | 39.13 | 47.19 | 78.33 | 61.22 | 54.18 | 61.22 |
| Tax % | 32.0% | 27.0% | 29.0% | 28.0% | 25.0% | 26.0% | 22.0% | 24.0% | 23.0% | 22.0% | 24.0% | — |
| Exceptional items | 0.12 | 2.14 | 2.71 | 1.39 | 1.05 | 5.95 | 1.98 | 3.23 | 8.18 | 9.74 | 4.72 | — |
| Net Profit | 25.95 | 19.96 | 16.97 | 22.95 | 13.98 | 27.96 | 30.95 | 35.96 | 59.85 | 46.94 | 40.96 | 43.94 |
| EPS (Rs) | 2.58 | 2.01 | 1.66 | 2.34 | 1.44 | 2.85 | 3.06 | 3.62 | 6.00 | 4.74 | 4.11 | 4.45 |
| Dividend payout % | 24.0% | 31.0% | 42.0% | 29.0% | 48.0% | 26.0% | 29.0% | 28.0% | 21.0% | 16.0% | 37.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.99 | 12.96 | 12.95 | 12.95 | 12.96 | 12.95 | 24.90 | 24.90 | 24.92 | 24.92 | 24.92 | 49.81 |
| Reserves | 97.05 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| Borrowings | 0.00 | 1.99 | 0.00 | 1.99 | 4.00 | 44.88 | 13.96 | 3.99 | 0.99 | 2.99 | 10.98 | 0.00 |
| Other Liabilities | 66.67 | 70.66 | 47.77 | 56.73 | 70.66 | 118 | 127 | 128 | 162 | 151 | 169 | 204 |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 325 | 332 | 346 | 404 | 445 | 506 | 556 |
| Fixed Assets | 8.97 | 17.96 | 16.94 | 16.96 | 20.92 | 83.76 | 70.75 | 60.85 | 52.88 | 48.89 | 57.86 | 56.79 |
| CWIP | 0.00 | 0.00 | 0.00 | 6.01 | 34.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 42.88 | 42.93 | 69.80 | 65.87 | 38.93 | 79.76 | 30.90 | 42.87 | 90.78 | 96.79 | 106 | 83.77 |
| Other Assets | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 415 |
| Inventories | 16.05 | 24.07 | 30.08 | 32.12 | 43.15 | 61.16 | 81.30 | 80.27 | 73.27 | 75.22 | 74.21 | 148 |
| Trade receivables | 67.87 | 74.82 | 56.92 | 70.94 | 74.92 | 80.91 | 107 | 136 | 171 | 190 | 216 | 239 |
| Cash & equivalents | 14.01 | 12.99 | 6.01 | 8.01 | 11.01 | 3.01 | 20.01 | 16.01 | 7.01 | 8.01 | 20.01 | 8.01 |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 325 | 332 | 346 | 404 | 445 | 506 | 556 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 19.04 | 16.02 | 26.05 | 2.01 | 7.02 | 49.06 | −19.05 | 29.04 | 54.13 | 13.02 | 37.06 | −3.01 |
| Cash from investing activity | −11.98 | −4.99 | −19.95 | 1.99 | 2.99 | −76.88 | 51.88 | −7.99 | −42.96 | 0.99 | −19.95 | 17.96 |
| Cash from financing activity | −7.97 | −8.97 | −3.99 | −4.99 | −6.98 | 21.94 | −32.87 | −18.95 | −11.96 | −8.97 | −4.99 | −25.93 |
| Net cash flow | −1.01 | 2.01 | 2.01 | −1.01 | 3.01 | −5.02 | 0.00 | 2.01 | −2.01 | 5.02 | 12.05 | −12.04 |
| Capex | 0.99 | 11.01 | 1.01 | 7.01 | 29.02 | 35.98 | 5.99 | 2.01 | 2.01 | 5.01 | 20.01 | 8.01 |
| Free cash flow | 18.06 | 6.02 | 25.07 | −5.02 | −22.06 | 13.03 | −25.07 | 27.08 | 52.16 | 8.02 | 17.05 | −11.05 |
| CFO / OP % | 96.0% | 78.0% | 149.0% | 49.0% | 56.0% | 232.0% | −20.0% | 80.0% | 130.0% | 42.0% | 78.0% | 16.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 89 | 85 | 101 | 110 | 86 | 97 | 91 | 103 | 119 | 108 | 120 | 114 |
| Inventory days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash conversion cycle | 37 | 43 | 71 | 69 | 62 | 29 | 49 | 63 | 47 | 59 | 60 | 90 |
| Working capital days | 44 | 49 | 80 | 81 | 66 | −9 | 58 | 69 | 62 | 70 | 69 | 93 |
| ROCE % | 33.1% | 35.1% | 19.1% | 14.1% | 19.1% | 10.1% | 16.1% | 18.1% | 19.1% | 26.1% | 17.0% | 15.1% |
For the Jun 2026 quarter, Anuh Pharma reported sales of ₹195 Cr, up 4.3% year on year and net profit of ₹10.98 Cr, up 37.6% year on year. The operating margin was 8.0%.
Anuh Pharma's sales for the year to Mar 2026 were ₹776 Cr; over the last twelve months they were ₹782 Cr.
Net profit for the year to Mar 2026 was ₹40.96 Cr, and ₹43.94 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.45.
Anuh Pharma reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹8.01 Cr.
Cash from operations was −₹3.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹11.05 Cr.